E. Ellis-Grosse

发表

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.

B. Cirincione, S. Bhavnani, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia

Ronald N. Jones, R. Wunderink, J. Rello, 2017, Antimicrobial Agents and Chemotherapy.

Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves

P. Rhomberg, D. Shortridge, R. Flamm, 2019, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

M. Beuran, A. Razbadauskas, N. Dartois, 2008, The Journal of antimicrobial chemotherapy.

Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae

G. Rao, Rajnikant Sharma, E. Ellis-Grosse, 2017, Antimicrobial Agents and Chemotherapy.

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

E. Loh, T. Babinchak, A. Yellin, 2005, BMC infectious diseases.

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

E. Loh, N. Dartois, T. Babinchak, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial

L. Rice, P. Eckburg, K. Kaye, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

B. Cirincione, J. Korth-Bradley, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Tigecycline: a case study

S. Projan, E. Loh, P. Petersen, 2007, Expert opinion on drug discovery.

The Efﬁcacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections: Analysis of Pooled Clinical Trial Data

E. Loh, N. Dartois, T. Babinchak, 2005 .

Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

M. Beuran, G. Barauskas, E. Loh, 2005, International journal of surgery.

The pharmacokinetic and pharmacodynamic profile of tigecycline.

P. Ambrose, T. Grasela, A. Meagher, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

G. Drusano, S. Bhavnani, P. Ambrose, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.

R. Postier, E. Loh, S. Klein, 2004, Clinical therapeutics.

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

J. Korth-Bradley, K. Rodvold, M. Gotfried, 2006, The Journal of antimicrobial chemotherapy.

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

E. Loh, J. Embil, E. Ellis-Grosse, 2005, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent

P. Ambrose, T. Grasela, A. Meagher, 2005 .

Frequentist and Bayesian Pharmacometric-Based Approaches To Facilitate Critically Needed New Antibiotic Development: Overcoming Lies, Damn Lies, and Statistics

Paul G. Ambrose, George L. Drusano, G. Drusano, 2011, Antimicrobial Agents and Chemotherapy.

Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam

E. Loh, J. Gardovskis, N. Dartois, 2005, Antimicrobial Agents and Chemotherapy.

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

E. Loh, N. Dartois, T. Babinchak, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers

E. Wenzler, K. Rodvold, E. Ellis-Grosse, 2017, Antimicrobial Agents and Chemotherapy.

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Arthur J. L. Cooper, N. Dartois, T. Babinchak, 2008, The Journal of antimicrobial chemotherapy.

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

D. Andes, P. Ambrose, A. Lepak, 2017, Antimicrobial Agents and Chemotherapy.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model

J. McCauley, S. Bhavnani, P. Ambrose, 2015, Antimicrobial Agents and Chemotherapy.

Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)

L. Rice, P. Eckburg, K. Kaye, 2017 .

Activity of fosfomycin when tested against US contemporary bacterial isolates.

P. Rhomberg, D. Shortridge, R. Flamm, 2019, Diagnostic microbiology and infectious disease.

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model

J. McCauley, S. Bhavnani, P. Ambrose, 2016, Antimicrobial Agents and Chemotherapy.

Exposure-response analyses of tigecycline tolerability in healthy subjects.

E. Ludwig, T. Grasela, J. Passarell, 2009, Diagnostic microbiology and infectious disease.

Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation

G. Drusano, J. Korth-Bradley, S. Bhavnani, 2007, Antimicrobial Agents and Chemotherapy.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

B. Cirincione, P. Ambrose, J. Passarell, 2007, Antimicrobial Agents and Chemotherapy.

Drug Development Process and Regulatory Science

J. Gobburu, E. Ellis-Grosse, 2016 .

Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.

G. Sutton, D. Fouts, R. Bonomo, 2019, The Journal of infectious diseases.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

B. Cirincione, P. Ambrose, J. Passarell, 2007, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites

A. Patat, D. Guyader, E. Ellis-Grosse, 2002, Hepatology.

Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae.

G. Rao, Rajnikant Sharma, E. Ellis-Grosse, 2022, International Journal of Antimicrobial Agents.

The pharma company view

E. Ellis-Grosse, R. Brenner, 2006, Nature Biotechnology.

The pharmacokinetic and pharmacodynamic profile of tigecycline.

P. Ambrose, T. Grasela, A. Meagher, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

G. Drusano, S. Bhavnani, P. Ambrose, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.